Idiopathic thrombocytopenic purpura and autoimmune neutropenia induced by prolonged use of nivolumab in Hodgkin’s lymphoma
Authors:
- 4 April 2017
- journal article
- research article
- Published by Elsevier in Annals of Oncology
- Vol. 28 (7) , 1675-1676
Abstract
PD-1 antibody-associated hematological adverse events have been extremely rare in the clinical trials of both nivolumab and pembrolizumab so far. In Hodgkin’s lymphoma (HL), 4/23 patients (17%) reported thrombocytopenia, 1 patient had grade 3 thrombocytopenia from MDS [1].Keywords
This publication has 5 references indexed in Scilit:
- Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trialThe Lancet Oncology, 2016
- Immune thrombocytopenia exacerbated by nivolumab in a patient with non-small-cell lung cancerCancer Treatment Communications, 2016
- Idiopathic thrombocytopenic purpura induced by nivolumab in a metastatic melanoma patient with elevated PD-1 expression on B cellsAnnals of Oncology, 2015
- PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's LymphomaNew England Journal of Medicine, 2015
- Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphomaBlood, 2010